Comparative Pharmacology
Head-to-head clinical analysis: KERLONE versus NADOLOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KERLONE versus NADOLOL.
KERLONE vs NADOLOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure.
Non-selective beta-adrenergic receptor antagonist (beta-blocker) that competitively blocks beta1 and beta2 receptors, reducing heart rate, myocardial contractility, and blood pressure.
10 mg orally once daily; may increase to 20 mg once daily if needed. Maximum 20 mg/day.
40 to 80 mg orally once daily, may be increased at 3-7 day intervals up to 240 mg once daily.
None Documented
None Documented
Terminal elimination half-life is 8-12 hours in healthy adults; may extend to 15-20 hours in renal impairment (CrCl <30 mL/min).
Clinical Note
moderateNadolol + Digitoxin
"Nadolol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateNadolol + Deslanoside
"Nadolol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateNadolol + Acetyldigitoxin
"Nadolol may increase the bradycardic activities of Acetyldigitoxin."
Clinical Note
moderateNadolol + Ouabain
"Nadolol may increase the bradycardic activities of Ouabain."
Terminal elimination half-life: 14–24 hours (average 20 hours); prolonged in renal impairment (up to 45 hours) allowing once-daily dosing
Primarily renal excretion of unchanged drug and metabolites (70-80% unchanged; 20-30% as glucuronide or sulfate conjugates). Biliary/fecal excretion accounts for less than 5%.
Renal (unchanged drug) 75-85%; fecal/biliary <5%
Category C
Category C
Beta-Blocker
Beta-Blocker